Invivyd, Inc. announced the appointment of Robert Allen as chief scientific officer, and Stacy Price as chief technology and manufacturing officer. In his new role, Dr. Allen will oversee the scientific direction of the company and has responsibility for supporting the discovery of therapies across Invivyds pipeline. Dr. Allen brings more than 30 years of experience across the infectious disease space.

Prior to joining Invivyd, he served as the chief scientific officer of SmartPharm Therapeutics, a subsidiary of Sorrento Therapeutics, where he led efforts to develop gene-encoded monoclonal antibodies (mAbs) for COVID-19 that could be quickly adapted to respond to emerging variants of concern. Prior to his time at SmartPharm Therapeutics, he held multiple senior scientific roles across the pharmaceutical and biotechnology industries including Sorrento Therapeutics, SIGA Technologies, and the Oregon Translational Research and Development Institute. Dr. Allen earned a Ph.D. in microbiology from Columbia University, a M.S. in applied biology from Georgia Institute of Technology, and a B.S. in biology from Rhodes College.

He has published extensively in the field of virology and completed his postdoctoral training in virology at Washington University in St. Louis and Emory University. Robbies deep experience in infectious disease and his scientific expertise in monoclonal antibodies are an excellent fit with the Invivyd team, said David Hering, chief executive officer of Invivyd.

As new CSO, Robbie will be an integral member of the leadership team, leading work to identify and engineer a pipeline of antibodies designed to keep pace with viral evolution. He is critical to ensuring Invivyd delivers on the promise of platform and pipeline. Stacy Price joined Invivyd in March 2023 as chief technology and manufacturing officer, bringing 30 years of experience in commercial and clinical biotechnology operations management to her new role.

In this position, she will lead the chemistry, manufacturing and controls (CMC) programs and technical operations functions to hone the processes that are the foundation of Invivyds programs. Prior to joining Invivyd, Ms. Price was the chief technical officer at Akouos, and the senior vice president of technical operations at Ziopharm Oncology where she established and led the development and manufacturing capabilities and functions. Prior to Ziopharm she held multiple operations leadership roles of increasing responsibility, delivering strategic and innovative solutions at Shire, TKT and Serono. She earned a M.S. in biochemical engineering and a B.S. in chemical engineering from Tufts University.

Ms. Price succeeds Dr. Rebecca Dabora, Invivyds former chief technology and manufacturing officer, who has transitioned into a consulting role with Invivyd. Stacy is a proven technology leader with a distinguished track record of innovation and operations management within the pharmaceutical industry, said Mr. Hering. She is an outstanding addition to team and has the technical depth, experience and skills to maximize the impact and effectiveness of Invivyds powerful platform approach, which believe will ultimately provide people who are immunocompromised or otherwise vulnerable with superior protection from viral diseases, starting with COVID-19.